The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors

Leukemia Research

Volumn 20, Issue 1, 1996, Pages 57-63

  Condiotti, Reba ^a   Slavin, Shimon ^a   Barak, Vivian ^a   Nagler, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Immunomodulator; Immunotherapy; Linomide; NK cells

Indexed keywords

CD3 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; ROQUINIMEX; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030041952     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00110-7     Document Type: Article

References (40)

1. Kolb H. J., Mittermuller J., Clemm Ch., Holler E., Ledderose G., Brehm G., Heim M. and Wilmanns W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 6, 2462.
2. Porter D. L., Roth M. S., McGarigle C., Ferrara J. L. M. & Antin J. H. (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl. J. Med. 330, 100.
3. Helg C., Roux E., Beris P., Cabrol C., Wacker P., Darbellay R., Wyss M., Jeannet M., Chapuis B. & Roosnek E. (1993) Adoptive immunotherapy for recurrent CML after BMT. BMT 12, 125.
4. Bar B. M. A. M., Schattenberg A., Mensink E. J. B. M., Van Kessel A. G., Smetsers T. F. C. M., Knops G. H. J. N., Linders E. H. P. & De Witte T. (1993) Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 11, 513.
5. Jiang Y. Z., Cullis J. O., Kanfer E. J., Goldman J. M. & Barrett A. J. (1993) T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. BMT 11, 133.
6. Weiss L., Weigensberg M., Morecki S., Bar S., Cobbold S., Waldmann H. & Slavin S. (1990) Characterization of effector cells of graft vs. leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol. Immunother. 31, 236.
7. + T cell activity. J. Immunol. 150, 197.
8. Mehta J. (1993) Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk. Lymph. 10, 427.
9. Ilback N. G., Fohlman J., Slorach S. & Friman G. (1989) Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine coxsackievirus B3 myocarditis. J. Immunol. 142, 3225.
10. Larsson E. L., Joki A. & Stalhandske T. (1987) Mechanism of action of the new immunomodulator LS 2616 on T cell responses. Int. J. Immunopharmacol. 9, 425.
11. Kalland T., Alm G. & Stalhandske T. (1985) Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 134, 3956.
12. Kalland T. (1990) Regulation of natural killer progenitors. J. Immunol. 144, 4472.
13. Kalland T. (1986) Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma Cancer Res. 46, 3018.
14. Harning R., Koo G. C. & Szalay J. (1989) Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest. Opthalmol. Vis. Sci. 30, 1909.
15. Harning R., Koo G. C. & Szalay J. (1990) Immune regulation of metastasis from in vivo derived syngeneic murine melanoma. Reg. Immunol. 3, 97.
16. Ter-Grigorov V., Slavin S., Liubashevsky E. & Trainin Z. Successful treatment of Rauscher retrovirus-induced leukemia in mice with the immunomodulator LS 2616 (Submitted).
17. Bergh J., Totterman T. H., Termander B., Jansson T. & Nilsson B. (1989) Marked activation of the immune system by linomide in cancer patients. A phase I study. 5th ECCO Meeting, London.
18. Bengtsson M., Simonsson B., Carlsson K., Nilsson B., Smedmyr B., Termander B., Oberg G. & Totterman T. H. (1992) Stimulation of NK cell, T cell and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplant 53, 882.
19. Rowe J. M., Ryan D. H., Nilsson B. I., Liesveld J. L., DiPersio J. F., Rapoport A. P., Abboud C. N., Larsson L., Packman C. H., Duerst R. E. & Simonsson B. (1994) Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by Roquinimex. Blood 10 (Suppl. 1), 204a (abstr.).
20. Philips J. H. & Lanier L. L. (1987) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Expl Med. 164, 814.
21. Nagler A., Lanier L. L., Cwirla S. & Phillips J. H. (1989) Comparative studies of human FcR III-positive and negative natural killer cells. J. Immunol. 143, 3183.
22. + hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD 34 immunoselection. Expl Hematol. 22, 1134.
23. Nagler A., Lanier L. L. & Phillips J. H. (1988) The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J. Immunol. 143, 3183.
24. Wagner D. K., Kiwanuka J., Edwards B. K., Rusin L. A., Nelson D. L. & Magrath I. T. (1987) Serum interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J. Clin. Oncol. 5, 1262.
25. De Vries J. E., Figdor C. G. & Spits H. (1982) Regulation of NK activity against adherent tumor target cells by monocyte subpopulation, interleukin-2 and interferons. In NK Cells and Other Natural Effector Cells (Herberman R. B., Ed.), pp. 657-668. Academic Press, New York.
26. Henney C. S., Kuribayashi K., Kern D. E. & Gillis S. (1981) Interleukin-2 augments natural killer cell activity. Nature 291, 335.
27. Gidlund M., Orn A., Wigzell H., Senik A. & Gresser I. (1978) Enhanced NK activity in mice infected with Interferon and Interferon inducers. Nature 223, 259.
28. Alleva D. G., Burger C. J. & Elgert K. D. (1993) Tumor-induced macrophage tumor necrosis factor-alpha production suppresses autoreactive T cell proliferation. Immunobiology 188, 430.
29. Hernandez Caselles T. & Stutman O. (1993) Immune functions of tumor necrosis factor. I. Tumor necrosis factor induces apoptosis of mouse thymocytes and can also stimulate or inhibit IL-6-induced proliferation depending on the concentration of mitogenic costimulation CD2 antibodies. J. Immunol. 151, 3999.
30. Hassan J. & Reen D. J. (1994) Interleukin-1 augments the diminished interleukin-2 mRNA expression and proliferative response of neonatal T lymphocytes to anti-CD2 antibodies. Scand. J. Immunol 39, 597.
31. Yui S., Yang D. & Yamazaki M. (1993) Heat stable interleukin-1 activity and inflammatory thymocyte proliferation in inflammatory polymorphonuclear leukocytes. Biol. Pharmacol. Bull. 16, 1150.
32. Morecki S., Nagler A., Puyesky Y., Nabet C., Condiotti R., Pick M., Gan S. & Slavin S. (1993) Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity. Lymph. Cyt. Res. 12, 159.
33. Bengtsson M., Geijerstam E., Karlsson C., Simonsson B., Smedmyr B., Oberg G. & Totterman T. H. (1992) The novel immunomodulator Linomide enhances the production of several cytokines after ABMT. 18th EBMT, Stockholm (abstr.).
34. Stalhandske T. & Kalland T. (1986) Effects of the novel immunomodulator linomide (LS 2616) on the delayed hypersensitivity reaction to bordetella pertussis in the rat. Immunopharmacology 11, 87.
35. Gonzalo J. A., Gonzalez-Garcia A., Kalland T., Hedlund G., Martinez A. C. & Kroemer G. (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur. J. Immunol. 24, 48.
36. Tarkowski A., Gunnarson K1, Nilsson L. A., Lindhom L. & Stalhanske T. (1986) Successful treatment of autoimmunity in MRL/I mice with LS 2616, a new immunomodulator. Arth. Rheum. 2, 1405.
37. Tarkowski A., Gunnarson K. & Stalhandske T. (1986) Effect of LS 2616 administration upon autoimmune disease of (NZBXNZW) F1 hybrid mice. Immunology 59, 589.
38. Bjork J. & Kleinau S. (1989) Paradoxical effects of LS 2616 (Linomide) treatment in type II collagen arthritis model in mice. Agents-Actions 27, 319.
39. Karussis D. M., Slavin S., Vourka-Karussis U., Lehmann D., Mizrachi-Koll R., Ovadia H., Kalland T. & Abramsky O. (1993) Successful treatment of acute and of chronic-relapsing experimental autoimmune encephalomyelitis by quinoline-3-carboximide (linomide) in the absence of systemic immunosuppression. Proc. natn. Acad. Sci. U.S.A. 90, 6400.
40. Gross D. J., Sidi H., Kalland T., Rosemann E., Weiss L. & Slavin S. (1995) Prevention of diabetes in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 37, 1194.